Disclosure: The study to which this correspondence refers was Editors’ Note: After review by the Editors and fur- sponsored by Pozen, Inc., and supported by GlaxoSmithKline, ther clarification by the authors, it was determined Park, NC. S.D. Silberstein is on the Advisory that Cynthia Toso played a role in drafting the origi- Panel or Speaker’s Bureau for , AstraZeneca, Endo Phar- nal Silberstein et al. manuscript. Ms. Toso was in- maceuticals, GlaxoSmithKline, Medtronic, Merck, Ortho- McNeil, , Pozen, and Valeant Pharmaceuticals. He receives cluded in the Acknowledgment but should have been ® research support from Abbott, Advanced Bionics, AGA, Ad- included in the byline as a coauthor. Neurology ’s vanced Neuro-Modulation Systems, Allergan, AstraZeneca, policy, effective December 15, 2006, states: “Manu- Endo Pharmaceuticals, Lilly, GlaxoSmithKline, Medtronic, scripts submitted for publication must list all au- Merck, OrthoMcNeil, Pfizer, Pozen, Pro-Ethic, Valeant Phar- thors, including the person who drafted the original maceuticals, and Vernalis. L.K. Mannix has served on the Advi- manuscript. This includes paid or unpaid medical sory Board, Speaker’s Bureau, or as a consultant for Allergan, Endo Pharmaceuticals, GlaxoSmithKline, Merck, OMN, and writers (‘ghost writers’).” A Correction noting the er- Pfizer. She also receives research grants from Allergan, Endo ror is included in this issue. Pharmaceuticals, GlaxoSmithKline, Merck, OMN, Pozen, and Copyright © 2009 by AAN Enterprises, Inc. Alexza. J. Goldstein has served as a Consultant and/or served on Advisory Boards, Speaker Bureaus, conducted and/or received 1. Silberstein SD, Mannix LK, Goldstein J, et al. Multi- research support from Abbott Laboratories, Agouron Pharma- mechanistic (-naproxen) early intervention for ceuticals, Allergan Inc., Almirall, Alza Pharmaceuticals, Applied the acute treatment of . Neurology 2008;71:114– Analytical Industries, AstraZeneca, Corporation, Boehr- 121. inger Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Bristol- 2. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and Myers Products, Capnia Inc., Carnrick Laboratories, naproxen sodium for the acute treatment of migraine. Inc., Corcept Therapeutics, Daiichi Pharma, Eisai Inc., Headache 2005;45:983–991. Elan Pharmaceuticals, Eli Lilly and Company, Forest Pharma- 3. Available at: www.drugstore.com and www.shopping.com. ceuticals, Fujisawa Healthcare Inc., GlaxoSmithKline, Janssen/ Accessed August 1, 2008. Johnson and Johnson, RWJohnson Pharmaceutical Research 4. Winner P, Landy S, Richardson M, Ames M. Early inter- Institute, McNeil Consumer and Specialty Pharmaceuticals, vention in migraine with sumatriptan tablets 50 mg versus Merck and Company, Pharmaceuticals, NPS Pharmaceuti- 100 mg: a pooled analysis of data from six clinical trials. cal, Neo Therapeutic, Pharmaceuticals, Ortho McNeil Clin Ther 2005;27:1785–1794. Pharmaceuticals, Parke-Davis, Pfizer Inc., Pharmacia, Pharmacia 5. Fox AW, Keywood C, Sheftell FD, Spierings ELH, and Upjohn, Pozen, Proctor&Gamble, Renovis Inc., Roche Phar- Winner P. Comparison of therapeutic gain with therapeu- maceuticals, Saegis Pharmaceuticals Inc., Sandoz Pharmaceuticals, tic ratio for the assessment of selective 5HT1B/1D agonist -Synthelabo Inc., Schwarz Bioscience, GD Searle, Syntex, efficacy in migraine. Headache 2002;42:680–688. UCB Pharma Inc., Vanguard Medica, Vernalis, Winston Laborato- 6. Goadsby PJ, Ferrari MD, Lipton RB. Therapeutic gain or ries, and -Ayerst. J.R. Couch has received research support therapeutic ratio? Headache 2003;43:814–815; author re- from GlaxoSmithKline, Astra , Merck, Pfizer, Ortho- ply 815–816. McNeil, and Schwarz. He has also participated in Speakers Bureaus 7. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users’ or Advisory Boards for GlaxoSmithKline, Astra Zeneca, Merck, guides to the medical literature: XIX: applying clinical trial Pfizer, and Ortho-McNeil. S.C. Byrd, M.H. Ames, S.A. Mc- results B Guidelines for determining whether a drug is ex- Donald, and S.E. Lener are current employees of GlaxoSmithKline, erting (more than) a class effect. JAMA 1999;282:1371– and M.H. Ames carried out the biostatistical analysis. 1377.

CORRECTION Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine In the article “Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine” by S.D. Silberstein et al. (Neurology® 2008;71:114–121), the authors include Cynthia Toso, PharmD, in the Acknowledgment. Dr. Toso should have been included in the byline as an author for her role in helping to draft the original manuscript. Disclosures: Cynthia Toso received funding for her work on this project and other writing-related projects from GlaxoSmithKline. She is a former employee of GlaxoSmithKline. Her husband is an employee of and has equity interests in GlaxoSmithKline.

Neurology 72 April 14, 2009 1369 Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine Neurology 2009;72;1369 DOI 10.1212/01.wnl.0000344301.82495.c6

This information is current as of April 13, 2009

Updated Information & including high resolution figures, can be found at: Services http://n.neurology.org/content/72/15/1369.full

Permissions & Licensing Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions Reprints Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology ® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.